Elekta AB stock (SE0000163628): cancer care specialist in focus after recent earnings and outlook

Radiation oncology player Elekta AB remains in the spotlight after releasing fiscal Q3 2025/26 results and updating its full?year outlook. US investors watch the Swedish medtech group for its global installed base and exposure to hospital capital spending.

Elekta AB, a Swedish specialist for radiation oncology equipment and software, recently reported results for its fiscal third quarter 2025/26 and reiterated its financial outlook, keeping investor attention on execution in a demanding hospital capital spending environment, according to Elekta investor relations as of 03/26/2026 and coverage from Reuters as of 03/26/2026.

As of: 15.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Elekta AB
• Sector/industry: Medical technology, radiation oncology
• Headquarters/country: Stockholm, Sweden
• Core markets: Cancer treatment centers and hospitals worldwide
• Key revenue drivers: Linear accelerators, Gamma Knife radiosurgery, oncology software and service contracts
• Home exchange/listing venue: Nasdaq Stockholm (EKTA B); US OTC market (EKTAF ADR)
• Trading currency: Swedish krona on Nasdaq Stockholm; US dollar for ADR

Elekta AB: core business model

Elekta AB focuses on technologies that support radiation-based cancer care, including linear accelerators for external beam radiotherapy, stereotactic radiosurgery systems such as Gamma Knife, and software platforms that support planning, delivery, and management of treatments, as described in the company’s profile on Elekta investor relations as of 03/26/2026.

The company generates revenue from the sale of new equipment, from accompanying software licenses, and from a large installed base that requires recurring service, upgrades, and replacement parts; this mix of upfront and recurring income is highlighted in Elekta’s fiscal 2024/25 annual reporting, according to Elekta reports and presentations as of 06/05/2025.

In addition to hardware and software, Elekta offers training and clinical support services to help hospitals run radiotherapy departments efficiently, an important differentiator in markets where staffing and workflow constraints can limit adoption of new treatment technologies, as noted by Bloomberg company overview as of 04/15/2026.

Main revenue and product drivers for Elekta AB

According to its fiscal Q3 2025/26 report, Elekta’s main revenue contributors are its radiotherapy and radiosurgery systems and related services, with the company highlighting growth in orders for linac systems and continued demand for Gamma Knife solutions for brain tumors and neurological conditions, based on Elekta financial information as of 03/26/2026.

Software is another important driver, particularly oncology information systems and treatment planning platforms that integrate imaging, planning, and delivery; Elekta reported increased software and services revenue in its fiscal 2024/25 results, pointing to a stronger installed base and more comprehensive digital offerings, according to Elekta reports and presentations as of 06/05/2025.

Service contracts tied to installed equipment provide a stream of recurring revenue and help smooth the impact of sometimes cyclical hospital capital spending; management emphasized that service and software now account for a significant share of net sales and contribute to margin resilience, as described in commentary accompanying the Q3 2025/26 results on Elekta financial information as of 03/26/2026.

Industry trends and competitive position

Radiation oncology is influenced by demographic aging, rising cancer incidence, and the ongoing shift toward more precise, image-guided treatments; Elekta positions itself as a key supplier in this niche alongside other large medtech players, according to sector analysis from S&P Global Market Intelligence as of 02/20/2026.

The company faces competition in linear accelerators and oncology information systems but maintains a leading position in dedicated stereotactic radiosurgery with its Gamma Knife platform; this segment benefits from high clinical specialization and long customer relationships with major neurosurgery centers, as highlighted in Elekta reports and presentations as of 06/05/2025.

Market research firms note that hospitals evaluate vendors not only on acquisition cost but also on workflow integration, uptime, and service quality; Elekta stresses its focus on lifecycle support and cloud-enabled software, while also navigating pricing pressure and procurement processes in publicly funded health systems, based on commentary summarized by EvaluateMedTech as of 01/30/2026.

Why Elekta AB matters for US investors

For US investors, Elekta provides exposure to global oncology equipment demand through its over-the-counter listing EKTAF, with the primary shares trading on Nasdaq Stockholm; this structure allows participation in international healthcare technology trends without investing directly on a European exchange, according to OTC Markets overview as of 04/18/2026.

Elekta reports that North America is one of its core regions, representing a meaningful share of orders and installed base, which ties the company’s performance to US hospital and cancer center investment cycles and reimbursement frameworks, as indicated in regional breakdowns in the fiscal 2024/25 annual materials from Elekta reports and presentations as of 06/05/2025.

Movements in the US dollar versus Swedish krona can also influence the reported value of Elekta’s US revenue and the ADR price, meaning US-based investors are indirectly exposed to currency effects alongside the underlying development of the cancer care equipment market, as underlined in risk disclosures within the company’s annual report presented on Elekta financial information as of 06/05/2025.

Conclusion

Elekta AB remains a focused player in radiation oncology systems and software, with its latest fiscal Q3 2025/26 report underscoring the importance of order intake, service revenue, and disciplined execution in a competitive hospital equipment market; for US investors accessing the stock via the EKTAF ADR, the company provides targeted exposure to cancer care technology and recurring service income while also involving region-specific reimbursement trends and currency effects that can influence returns over time.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.